A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of
BT-001 with repeated IT administrations alone and in combination with IV infusions of
pembrolizumab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Transgene
Collaborators:
BioInvent International AB Merck Sharp & Dohme LLC